Filing Details
- Accession Number:
- 0000899243-17-022966
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-29 17:15:35
- Reporting Period:
- 2017-09-28
- Accepted Time:
- 2017-09-29 17:15:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1559053 | Prothena Corp Plc | PRTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1708681 | M. Wagner Zago | C/O Prothena Biosciences Inc 331 Oyster Point Boulevard South San Francisco CA 94080 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, Par Value $0.01 Per Share | Acquisiton | 2017-09-28 | 900 | $6.41 | 900 | No | 4 | M | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2017-09-28 | 900 | $70.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (right to buy) | Disposition | 2017-09-28 | 900 | $0.00 | 900 | $6.41 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,100 | 2023-01-29 | No | 4 | M | Direct |
Footnotes
- The sales reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- The original grant was for 36,000 shares, of which 20,000 shares have been exercised and sold. The remaining shares underlying the option (15,100 shares) are fully vested and exercisable as of the date hereof.
Billionaire Hedge Funds
